Illumina, Inc. (NASDAQ:ILMN) Given Consensus Recommendation of “Hold” by Brokerages

Illumina, Inc. (NASDAQ:ILMN) has earned an average recommendation of “Hold” from the nineteen analysts that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $167.70.

ILMN has been the topic of several research reports. TD Cowen cut Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a report on Thursday, January 4th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. StockNews.com raised Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Illumina in a research report on Wednesday, April 10th. Finally, OTR Global reiterated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th.

Insider Transactions at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Illumina

Hedge funds have recently made changes to their positions in the stock. J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Illumina in the third quarter valued at about $29,558,000. International Assets Investment Management LLC raised its stake in Illumina by 210.5% in the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock valued at $6,711,000 after buying an additional 32,672 shares during the last quarter. Aquila Investment Management LLC raised its stake in Illumina by 150.0% in the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock valued at $3,481,000 after buying an additional 15,000 shares during the last quarter. Weil Company Inc. raised its stake in Illumina by 59.2% in the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock valued at $3,152,000 after buying an additional 8,539 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Illumina by 15.0% in the third quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company’s stock valued at $2,466,614,000 after buying an additional 2,336,935 shares during the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Price Performance

NASDAQ:ILMN opened at $117.43 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The business’s 50-day simple moving average is $133.37 and its two-hundred day simple moving average is $127.94. The stock has a market cap of $18.70 billion, a PE ratio of -16.00 and a beta of 1.19. Illumina has a 52 week low of $89.00 and a 52 week high of $229.58.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same period last year, the firm earned $0.14 earnings per share. The business’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, analysts forecast that Illumina will post 0.91 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.